Robert Gallo urged Francis Collins not to place every immunological egg in one basket. The real failure, I believe, was not pursuing enough alternative strategies or preserving scientific uncertainty.
And they wonder why so many people find the NHS and its GPs totally untrustworthy. Thank you Philip. There was little upside to their novel potion and an enormous amount of downside risk. So pleased I resisted the coercion.
I appreciate your work. But one day you will decide what side of the argument you believe. Dr Judy Mikovitz who speaks highly of Gallo wrote a significant book outlining the real agenda. And Sacha Latypova’s work on the Covid Chronicles provides all the receipts.
There was such a mad stampede to launch the new technology and make billions, even many waverers were swept along by the frenzy, leaving reason behind as if old fashioned and dated. Of course, then came the two years of madness. It might be a simplistic summary, Doctor, and if written as a prediction prior to 2020, it would have been dismissed as far fetched.
this artice was just after the meeting. they know nothing about heart damage
they got stanley perlman who looked at LNP heart damage in 2021
he says they have no information
but are looking forward to collecting some from the 'post-marketing' trial.
read his quote if nothing else - it was at 6 hours in on the youtube: "193rd VRBPAC"
FDA Sells Living Heart Tissue to Moderna for Experimentation
Would the FDA maim the young for money? NEVER! They will do it just because they are curious. We really need some Real World Data on this because we have ZERO. Moderna will go get the data for us.
Vaccines and Related Biological Products Advisory Committee — June 2026 Meeting
SUBJECT: Public Comment – MFLUSIVA (Influenza Vaccine, mRNA); BLA STN 125869/0
PURPOSE: To add to the record a concise, literature-anchored rationale regarding the distinct pharmacokinetic and biophysical profiles of mRNA lipid nanoparticle (LNP) platforms compared to traditional influenza vaccines.
Fixed Antigen Dosage vs. Cellular Transfection Kinetics
Traditional influenza vaccines deliver a precise, pre-measured dose of a static antigen that remains largely localized. Conversely, mRNA platforms utilize LNPs as transfection vehicles to deliver genetic blueprints, prompting host cells to manufacture the antigen in vivo. Because individual cellular uptake, translation efficiency, and the kinetics of antigen production vary among recipients, the internal pharmacokinetic profile differs fundamentally from conventional vaccines. Consequently, standard bioequivalence and safety models must account for these platform-specific variables.
Literature-Anchored Biophysical Considerations
1. Biomolecular Corona Formation and Biodistribution
Unlike traditional vaccines with highly predictable surface characteristics, LNPs adsorb host plasma proteins upon systemic entry, forming a dynamic "protein corona" (Cedervall et al., 2007; Monopoli et al., 2012). This biomolecular layer influences cellular targeting, interactions with receptor pathways, and clearance mechanisms (Francia et al., 2020; Schöttler et al., 2016). Characterizing these corona dynamics is critical to modeling LNP pharmacokinetics accurately across diverse patient populations.
2. Innate Immune and Complement Interactions
Synthetic lipid formulations can interact with the innate immune system, including the complement cascade (Moghimi et al., 2011). Transient complement activation by nanomedicines can influence early reactogenicity profiles and accelerate the rate of particle clearance by the mononuclear phagocyte system (Szebeni, 2005). This specific lipid-mediated pathway requires distinct safety and monitoring considerations not typically associated with highly purified traditional protein antigens.
3. Surface Interactions and Protein Conformation
The binding of plasma proteins to nanoparticle surfaces can induce localized changes in native protein secondary structure (Lynch & Dawson, 2008; Nel et al., 2009). These structural alterations can modify how the adsorbed proteins interact with cell-surface receptors (Fleischer & Payne, 2014). Understanding these soft-matter surface properties is necessary for mapping out downstream cellular interactions and verifying platform-specific biocompatibility.
4. Influence on Protein Microenvironments
In model environments, nanoscale surfaces can affect the local behavior and kinetics of surrounding macromolecules (Linse et al., 2007; Mahmoudi et al., 2013). The specific lipid composition, phase behavior, and surface charge density of an LNP dictate its immediate microenvironment. Evaluating these biophysical surface interactions is an established component of nanomedicine characterization.
References
Cedervall, T., Lynch, I., et al. (2007). Understanding the nanoparticle–protein corona. PNAS, 104(7), 2050–2055.
Fleischer, C. C., & Payne, C. K. (2014). Secondary structure of corona proteins determines cell surface receptors. J. Phys. Chem. B, 118(49), 14017–14026.
Francia, V., Schiffelers, R. M., Cullis, P. R., & Witzigmann, D. (2020). The biomolecular corona of lipid nanoparticles for gene therapy. Bioconjugate Chem., 31(9), 2046–2059.
Linse, S., Cabaleiro‑Lago, C., et al. (2007). Nucleation of protein fibrillation by nanoparticles. PNAS, 104(21), 8691–8696.
Lynch, I., & Dawson, K. A. (2008). Protein‑nanoparticle interactions. Nano Today, 3(1-2), 40–47.
Mahmoudi, M., Kalhor, H., Laurent, S., & Lynch, I. (2013). The protein corona slows amyloid beta fibrillation. ChemBioChem, 14(5), 568–572.
Moghimi, S. M., Peer, D., & Hunter, A. C. (2011). Activation of the complement system by nanomedicines. Adv. Drug Deliv. Rev., 63(12), 1000–1007.
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012). Biomolecular coronas provide the biological identity. Nat. Nanotechnol., 7(12), 779–786.
Nel, A. E., Mädler, L., et al. (2009). Understanding biophysicochemical interactions at the nano–bio interface. Nat. Mater., 8(7), 543–557.
Schöttler, S., et al. (2016). Protein adsorption is required for stealth effect of poly(ethylene glycol)-coated nanocarriers. Nat. Nanotechnol., 11(4), 372–378.
Szebeni, J. (2005). Complement activation‑related pseudoallergy: A new class of drug‑induced acute toxicity. Toxicology, 216(2-3), 106–121.
I've heard Billy say they were too slow with the rollout in 2021 and next time will have to be quicker; perhaps that's why we see the flu mrna now before the fall wave arrives..
Oh come now they knew allof this ....they were tasked with creating a shot that would elicit the bossche mutation and wipe us out before civilization collapses due to severe depletion of affordable energy....before starvation mass murder and cannibalism...
How else do you justify this unless the alternative is much more horrific
Fsteddy 💯 event 201 they planned for over 1 century if not more thanks to the Rot Childs banksters zio-technocrats globalists. It's just the beginning....
Legal Summary: Statutory Violations in mRNA-LNP Biologic Licensure Under 21 USC § 355
I. STATUTORY FRAMEWORK
The NDA/BLA stability and manufacturing requirements derive from four interdependent statutory and regulatory provisions, none of which contain emergency exceptions applicable to full licensure:
21 USC § 355(b)(1)(A) — Applicant must submit full reports of investigations demonstrating safety and effectiveness, plus a full description of manufacturing methods, facilities, and controls sufficient to preserve identity, strength, quality, and purity.
21 USC § 355(d)(7) — The Secretary shall refuse an application where manufacturing methods, facilities, or controls are inadequate to preserve identity, strength, quality, and purity. Mandatory, not discretionary.
21 CFR § 314.50(d)(1) — The CMC section must list all components, describe the function of each, and include full stability data on drug substance and drug product.
21 CFR § 211.166 — Requires a written stability testing program. Test results must determine storage conditions and expiration dates. Testing must use the product in the same container-closure system as marketed.
II. NO SUPERSEDING LEGISLATION
PREP Act (42 USC § 247d-6d): Provides tort liability immunity for covered countermeasures during a declared emergency. Does not amend § 355. Does not authorize licensure. Does not waive manufacturing, stability, or pharmacovigilance requirements. Codified in Title 42, not Title 21 — no conforming amendment to FD&C Act exists.
EUA Statute (21 USC § 360bbb-3): Authorizes temporary market access for unapproved products during emergencies. Creates a parallel pathway that bypasses § 355. Does not authorize use of EUA-era data as substitute for § 355 compliance upon BLA submission. Product exits EUA framework upon seeking full licensure.
PHS Act (42 USC § 262): Incorporates FD&C Act standards for biologics. Requires demonstration that product is safe, pure, and potent and that the facility ensures the product continues to be safe, pure, and potent. No emergency waiver provision.
FDAAA, 21st Century Cures Act, Defense Production Act: None amend § 355 stability or manufacturing requirements. None provide authority to waive pre-approval quality standards.
Executive Orders: Cannot amend statute. Reliance on executive action to justify deviation from § 355 is ultra vires.
The lipid nanoparticle delivery system was classified as an inert excipient. It is not inert. The LNP determines biodistribution, undergoes chemical degradation producing species of unknown toxicity, and has independent pharmacological activity (immune activation, complement activation, cytotoxicity). The function of each component was materially misdescribed on the application. A false description cannot satisfy § 355(b)(1)(A). The FDA lacked authority to approve an application containing a material misrepresentation of component function.
Clinical trial lots were small-batch, tightly controlled, and administered fresh. Commercial lots are manufactured at scale, held 6–24 months, and distributed through uncontrolled channels. Scale-up changes mixing kinetics, shear forces, and temperature gradients — all critical to LNP self-assembly. Aging produces chemical species absent from clinical material. The stability profile of fresh clinical lots is not representative of aged commercial lots. Testing the wrong product violates § 211.166. Failure to retain and examine representative commercial samples violates § 211.170.
Passive surveillance cannot detect subacute, cumulative toxicities from lipid oxidation and hydrolysis byproducts. Degradation products lack MedDRA codes. Injuries present as progressive dysfunction over months, not acute events. A pharmacovigilance system structurally incapable of detecting the most plausible injury mechanism for the product class does not satisfy § 355(k).
Violation 5: Unvalidated Use Conditions — 21 CFR § 211.111
Clinical trials used buffered diluents, controlled hold times, and refrigerated storage until administration. Real-world use involved unbuffered normal saline (variable pH), extended room-temperature hold times, and unmonitored temperature excursions. Each deviation requires validation data. None was generated. § 211.111 requires time limits for production phases to assure quality. Conditions of actual use were never incorporated into the stability program submitted with the application.
IV. LEGAL CONCLUSION
Each of the five violations independently renders the BLA approval unlawful. The violations are structural, not marginal — they go to the fundamental statutory prerequisites for licensure. No emergency statute amends, supersedes, or waives these requirements. The PREP Act is a liability shield, not a licensing authority. The EUA statute is a temporary access pathway, not a permanent approval mechanism. The FDA acted without statutory authority in approving an application that did not satisfy § 355.
Remedy sought: Vacatur of the biologics license. The license was issued without statutory authority. The product is on the market in violation of the FD&C Act.
And they wonder why so many people find the NHS and its GPs totally untrustworthy. Thank you Philip. There was little upside to their novel potion and an enormous amount of downside risk. So pleased I resisted the coercion.
I appreciate your work. But one day you will decide what side of the argument you believe. Dr Judy Mikovitz who speaks highly of Gallo wrote a significant book outlining the real agenda. And Sacha Latypova’s work on the Covid Chronicles provides all the receipts.
There was such a mad stampede to launch the new technology and make billions, even many waverers were swept along by the frenzy, leaving reason behind as if old fashioned and dated. Of course, then came the two years of madness. It might be a simplistic summary, Doctor, and if written as a prediction prior to 2020, it would have been dismissed as far fetched.
Very true
Cheers Dr. Phil.
The the Pfizer purple cap instructions were to use off the shelf local saline to dilute the nanoparticles.
Off the shelf saline has 100x more Endotoxin allowed than the shot did.
Might as well mix 4:1
Follow these instructions:
https://badprotein.substack.com/p/nanoparticles-hate-endotoxins
hi Dr. MacMillan,
just making the rounds of substack, dropping off easter eggs for all the kiddies..
i salute you!
BP
--
these are all comments sent to the 193rd VRBPAC meeting
there were a couple of eleventh hour submissions - the meeting was on June 18,
but pretty much all of these were sent before the cutoff at June 12
according to the FDA the VRBPAC committes had my comments in their hands before the meeting.
they did not put all of them up on the Regulations'gov website, but they allowed 16 of them
it was not a rulemaking meeting, and i intentionally used language to frame most of the comments
as supportive information to aid the committee in their decision.
please click these links and read them.
agree or disagree, they are part of the Offical Record.
1 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0006
2 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0007
3 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0008
4 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0009
5 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0011
6 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0018
7 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0020
8 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0023
9 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0028
10 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0033
11 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0034
12 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0044
13 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0045
14 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0046
15 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0047
16 =============================================
https://www.regulations.gov/comment/FDA-2026-N-4162-0025
--
Read this to find out about the study, and how it was conflicted
you should read this about the trial publishing by NEJM
https://badprotein.substack.com/p/lab-tweak-hypothesis
--
https://badprotein.substack.com/p/fda-sells-living-heart-tissue-to
this artice was just after the meeting. they know nothing about heart damage
they got stanley perlman who looked at LNP heart damage in 2021
he says they have no information
but are looking forward to collecting some from the 'post-marketing' trial.
read his quote if nothing else - it was at 6 hours in on the youtube: "193rd VRBPAC"
FDA Sells Living Heart Tissue to Moderna for Experimentation
Would the FDA maim the young for money? NEVER! They will do it just because they are curious. We really need some Real World Data on this because we have ZERO. Moderna will go get the data for us.
https://badprotein.substack.com/p/fda-sells-living-heart-tissue-to
--
This article goes through stanley perlman's CV and proves he know nothing about nanoparticles.
he makes and sells them though.
this is long - he is co-author with raplh baric on a paper or two
https://badprotein.substack.com/p/primum-non-curare
--
https://badprotein.substack.com/p/modernacarditis
here we talk about how subclinical scarring of the endothelium and heart is
the perfect thing for a postmarketing vaccine safety study.
join the army and get a shot
it's not just headshots anymore
-- this one came before - trying to mobilise interest
has articles for some of the other submissions to regulations.gov
https://badprotein.substack.com/p/gene-therapy-for-runny-noses
--
but read
https://badprotein.substack.com/p/lab-tweak-hypothesis
and
https://badprotein.substack.com/p/primum-non-curare
if you are serious.
Best!
BadProtein
-------------------
SAMPLE - DO NOT EAT
-------------------
Docket No. FDA-2026-N-4162
TO: Food and Drug Administration (FDA)
Vaccines and Related Biological Products Advisory Committee — June 2026 Meeting
SUBJECT: Public Comment – MFLUSIVA (Influenza Vaccine, mRNA); BLA STN 125869/0
PURPOSE: To add to the record a concise, literature-anchored rationale regarding the distinct pharmacokinetic and biophysical profiles of mRNA lipid nanoparticle (LNP) platforms compared to traditional influenza vaccines.
Fixed Antigen Dosage vs. Cellular Transfection Kinetics
Traditional influenza vaccines deliver a precise, pre-measured dose of a static antigen that remains largely localized. Conversely, mRNA platforms utilize LNPs as transfection vehicles to deliver genetic blueprints, prompting host cells to manufacture the antigen in vivo. Because individual cellular uptake, translation efficiency, and the kinetics of antigen production vary among recipients, the internal pharmacokinetic profile differs fundamentally from conventional vaccines. Consequently, standard bioequivalence and safety models must account for these platform-specific variables.
Literature-Anchored Biophysical Considerations
1. Biomolecular Corona Formation and Biodistribution
Unlike traditional vaccines with highly predictable surface characteristics, LNPs adsorb host plasma proteins upon systemic entry, forming a dynamic "protein corona" (Cedervall et al., 2007; Monopoli et al., 2012). This biomolecular layer influences cellular targeting, interactions with receptor pathways, and clearance mechanisms (Francia et al., 2020; Schöttler et al., 2016). Characterizing these corona dynamics is critical to modeling LNP pharmacokinetics accurately across diverse patient populations.
2. Innate Immune and Complement Interactions
Synthetic lipid formulations can interact with the innate immune system, including the complement cascade (Moghimi et al., 2011). Transient complement activation by nanomedicines can influence early reactogenicity profiles and accelerate the rate of particle clearance by the mononuclear phagocyte system (Szebeni, 2005). This specific lipid-mediated pathway requires distinct safety and monitoring considerations not typically associated with highly purified traditional protein antigens.
3. Surface Interactions and Protein Conformation
The binding of plasma proteins to nanoparticle surfaces can induce localized changes in native protein secondary structure (Lynch & Dawson, 2008; Nel et al., 2009). These structural alterations can modify how the adsorbed proteins interact with cell-surface receptors (Fleischer & Payne, 2014). Understanding these soft-matter surface properties is necessary for mapping out downstream cellular interactions and verifying platform-specific biocompatibility.
4. Influence on Protein Microenvironments
In model environments, nanoscale surfaces can affect the local behavior and kinetics of surrounding macromolecules (Linse et al., 2007; Mahmoudi et al., 2013). The specific lipid composition, phase behavior, and surface charge density of an LNP dictate its immediate microenvironment. Evaluating these biophysical surface interactions is an established component of nanomedicine characterization.
References
Cedervall, T., Lynch, I., et al. (2007). Understanding the nanoparticle–protein corona. PNAS, 104(7), 2050–2055.
Fleischer, C. C., & Payne, C. K. (2014). Secondary structure of corona proteins determines cell surface receptors. J. Phys. Chem. B, 118(49), 14017–14026.
Francia, V., Schiffelers, R. M., Cullis, P. R., & Witzigmann, D. (2020). The biomolecular corona of lipid nanoparticles for gene therapy. Bioconjugate Chem., 31(9), 2046–2059.
Linse, S., Cabaleiro‑Lago, C., et al. (2007). Nucleation of protein fibrillation by nanoparticles. PNAS, 104(21), 8691–8696.
Lynch, I., & Dawson, K. A. (2008). Protein‑nanoparticle interactions. Nano Today, 3(1-2), 40–47.
Mahmoudi, M., Kalhor, H., Laurent, S., & Lynch, I. (2013). The protein corona slows amyloid beta fibrillation. ChemBioChem, 14(5), 568–572.
Moghimi, S. M., Peer, D., & Hunter, A. C. (2011). Activation of the complement system by nanomedicines. Adv. Drug Deliv. Rev., 63(12), 1000–1007.
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012). Biomolecular coronas provide the biological identity. Nat. Nanotechnol., 7(12), 779–786.
Nel, A. E., Mädler, L., et al. (2009). Understanding biophysicochemical interactions at the nano–bio interface. Nat. Mater., 8(7), 543–557.
Schöttler, S., et al. (2016). Protein adsorption is required for stealth effect of poly(ethylene glycol)-coated nanocarriers. Nat. Nanotechnol., 11(4), 372–378.
Szebeni, J. (2005). Complement activation‑related pseudoallergy: A new class of drug‑induced acute toxicity. Toxicology, 216(2-3), 106–121.
Great post! An example of putting profit before science. Emergency Use Authorization isn't allowed If an existing anti-viral is proven effective.
I've heard Billy say they were too slow with the rollout in 2021 and next time will have to be quicker; perhaps that's why we see the flu mrna now before the fall wave arrives..
Oh come now they knew allof this ....they were tasked with creating a shot that would elicit the bossche mutation and wipe us out before civilization collapses due to severe depletion of affordable energy....before starvation mass murder and cannibalism...
How else do you justify this unless the alternative is much more horrific
Fsteddy 💯 event 201 they planned for over 1 century if not more thanks to the Rot Childs banksters zio-technocrats globalists. It's just the beginning....
I wonder if activated charcoal could Scrub your gut of spike proteins?
Never forget the Vehicle.
Legal Summary: Statutory Violations in mRNA-LNP Biologic Licensure Under 21 USC § 355
I. STATUTORY FRAMEWORK
The NDA/BLA stability and manufacturing requirements derive from four interdependent statutory and regulatory provisions, none of which contain emergency exceptions applicable to full licensure:
21 USC § 355(b)(1)(A) — Applicant must submit full reports of investigations demonstrating safety and effectiveness, plus a full description of manufacturing methods, facilities, and controls sufficient to preserve identity, strength, quality, and purity.
21 USC § 355(d)(7) — The Secretary shall refuse an application where manufacturing methods, facilities, or controls are inadequate to preserve identity, strength, quality, and purity. Mandatory, not discretionary.
21 CFR § 314.50(d)(1) — The CMC section must list all components, describe the function of each, and include full stability data on drug substance and drug product.
21 CFR § 211.166 — Requires a written stability testing program. Test results must determine storage conditions and expiration dates. Testing must use the product in the same container-closure system as marketed.
II. NO SUPERSEDING LEGISLATION
PREP Act (42 USC § 247d-6d): Provides tort liability immunity for covered countermeasures during a declared emergency. Does not amend § 355. Does not authorize licensure. Does not waive manufacturing, stability, or pharmacovigilance requirements. Codified in Title 42, not Title 21 — no conforming amendment to FD&C Act exists.
EUA Statute (21 USC § 360bbb-3): Authorizes temporary market access for unapproved products during emergencies. Creates a parallel pathway that bypasses § 355. Does not authorize use of EUA-era data as substitute for § 355 compliance upon BLA submission. Product exits EUA framework upon seeking full licensure.
PHS Act (42 USC § 262): Incorporates FD&C Act standards for biologics. Requires demonstration that product is safe, pure, and potent and that the facility ensures the product continues to be safe, pure, and potent. No emergency waiver provision.
FDAAA, 21st Century Cures Act, Defense Production Act: None amend § 355 stability or manufacturing requirements. None provide authority to waive pre-approval quality standards.
Executive Orders: Cannot amend statute. Reliance on executive action to justify deviation from § 355 is ultra vires.
III. FIVE STATUTORY VIOLATIONS
Violation 1: Component Misclassification — § 355(b)(1)(A); 21 CFR § 314.50(d)(1)(ii)(a)
The lipid nanoparticle delivery system was classified as an inert excipient. It is not inert. The LNP determines biodistribution, undergoes chemical degradation producing species of unknown toxicity, and has independent pharmacological activity (immune activation, complement activation, cytotoxicity). The function of each component was materially misdescribed on the application. A false description cannot satisfy § 355(b)(1)(A). The FDA lacked authority to approve an application containing a material misrepresentation of component function.
Violation 2: Inadequate Stability Controls — § 355(d)(7)
Shelf-life extensions relied on SLEP methodology developed for small-molecule drugs. SLEP assumes predictable Arrhenius degradation kinetics, well-characterized degradation products, and potency loss as primary failure mode. mRNA-LNP products exhibit autocatalytic lipid hydrolysis and oxidation, unknown degradation products, and delivery-system failure independent of mRNA integrity. Applying small-molecule protocols to complex biologics without validation rendered controls inadequate. § 355(d)(7) required refusal.
Violation 3: Lot Non-Equivalence — 21 CFR § 211.166, § 211.170
Clinical trial lots were small-batch, tightly controlled, and administered fresh. Commercial lots are manufactured at scale, held 6–24 months, and distributed through uncontrolled channels. Scale-up changes mixing kinetics, shear forces, and temperature gradients — all critical to LNP self-assembly. Aging produces chemical species absent from clinical material. The stability profile of fresh clinical lots is not representative of aged commercial lots. Testing the wrong product violates § 211.166. Failure to retain and examine representative commercial samples violates § 211.170.
Violation 4: Inadequate Pharmacovigilance — § 355(k); 21 CFR § 314.80
Passive surveillance cannot detect subacute, cumulative toxicities from lipid oxidation and hydrolysis byproducts. Degradation products lack MedDRA codes. Injuries present as progressive dysfunction over months, not acute events. A pharmacovigilance system structurally incapable of detecting the most plausible injury mechanism for the product class does not satisfy § 355(k).
Violation 5: Unvalidated Use Conditions — 21 CFR § 211.111
Clinical trials used buffered diluents, controlled hold times, and refrigerated storage until administration. Real-world use involved unbuffered normal saline (variable pH), extended room-temperature hold times, and unmonitored temperature excursions. Each deviation requires validation data. None was generated. § 211.111 requires time limits for production phases to assure quality. Conditions of actual use were never incorporated into the stability program submitted with the application.
IV. LEGAL CONCLUSION
Each of the five violations independently renders the BLA approval unlawful. The violations are structural, not marginal — they go to the fundamental statutory prerequisites for licensure. No emergency statute amends, supersedes, or waives these requirements. The PREP Act is a liability shield, not a licensing authority. The EUA statute is a temporary access pathway, not a permanent approval mechanism. The FDA acted without statutory authority in approving an application that did not satisfy § 355.
Remedy sought: Vacatur of the biologics license. The license was issued without statutory authority. The product is on the market in violation of the FD&C Act.
They knew this in 2020 but bypassed decades of immunological research. Also makes you think about that IgG4 effect.